TY - JOUR
T1 - Goal-Directed Rehabilitation Versus Standard Care for Individuals with Hereditary Cerebellar Ataxia
T2 - A Multicenter, Single-Blind, Randomized Controlled Superiority Trial
AU - Roberts, Melissa
AU - Williams, Shannon
AU - Chua, Jillian
AU - Grootendorst, Alison C.
AU - Agostinelli, Genevieve
AU - Grobler, Anneke C.
AU - Ross, Hannah L.
AU - Robinson, Amy
AU - Grove, Kristen
AU - Modderman, Gabrielle
AU - Price, Annabel
AU - Thomson, Megan
AU - Massey, Libby
AU - Liang, Christina
AU - Kumar, Kishore R.
AU - Dalziel, Kim
AU - Burns, Joshua
AU - Sue, Carolyn M.
AU - Pathirana, Pubudu N.
AU - Horne, Malcolm
AU - Gelfard, Nikki
AU - Curd, Helen
AU - Szmulewicz, David
AU - Corben, Louise A.
AU - Delatycki, Martin B.
A2 - Milne, Sarah C.
N1 - Publisher Copyright:
© 2024 American Neurological Association.
PY - 2025/3
Y1 - 2025/3
N2 - Objective: Rehabilitation is thought to reduce ataxia severity in individuals with hereditary cerebellar ataxia (HCA). This multicenter, randomized controlled superiority trial aimed to examine the efficacy of a 30-week goal-directed rehabilitation program compared with 30 weeks of standard care on function, ataxia, health-related quality of life, and balance in individuals with an HCA. Methods: Individuals with an autosomal dominant or recessive ataxia (aged ≥15 years) were enrolled at 5 sites in Australia. Participants were randomized (1:1) to receive rehabilitation (6 weeks of outpatient physiotherapy followed by a 24-week home exercise program) (n = 39) or continued their usual activity (n = 37). The primary outcome measure was the motor domain of the Functional Independence Measure (mFIM) at 7 weeks. Secondary outcomes included the Scale for the Assessment and Rating of Ataxia (SARA) and the SF-36v2, assessed at 7, 18, and 30 weeks. Outcome assessors were blinded to treatment allocation. Results: Seventy-one participants (rehabilitation, 37; standard-care, 34) were included in the intention-to-treat analysis. At 7 weeks, mFIM (mean difference 2.26, 95% confidence interval [CI]: 0.26 to 4.26, p = 0.028) and SARA (−1.21, 95% CI: −2.32 to −0.11, p = 0.032) scores improved after rehabilitation compared with standard care. Compared with standard care, rehabilitation improved SARA scores at 30 weeks (mean difference −1.51, 95% CI: −2.76 to −0.27, p = 0.017), but not mFIM scores (1.74, 95% CI: −0.32 to 3.81, p = 0.098). Frequent adverse events in both groups were fatigue, pain, and falls. Interpretation: Goal-directed rehabilitation improved function at 7 weeks, with improvement in ataxia and health-related quality of life maintained at 30 weeks in individuals with HCA, beyond that of standard care. ANN NEUROL 2024.
AB - Objective: Rehabilitation is thought to reduce ataxia severity in individuals with hereditary cerebellar ataxia (HCA). This multicenter, randomized controlled superiority trial aimed to examine the efficacy of a 30-week goal-directed rehabilitation program compared with 30 weeks of standard care on function, ataxia, health-related quality of life, and balance in individuals with an HCA. Methods: Individuals with an autosomal dominant or recessive ataxia (aged ≥15 years) were enrolled at 5 sites in Australia. Participants were randomized (1:1) to receive rehabilitation (6 weeks of outpatient physiotherapy followed by a 24-week home exercise program) (n = 39) or continued their usual activity (n = 37). The primary outcome measure was the motor domain of the Functional Independence Measure (mFIM) at 7 weeks. Secondary outcomes included the Scale for the Assessment and Rating of Ataxia (SARA) and the SF-36v2, assessed at 7, 18, and 30 weeks. Outcome assessors were blinded to treatment allocation. Results: Seventy-one participants (rehabilitation, 37; standard-care, 34) were included in the intention-to-treat analysis. At 7 weeks, mFIM (mean difference 2.26, 95% confidence interval [CI]: 0.26 to 4.26, p = 0.028) and SARA (−1.21, 95% CI: −2.32 to −0.11, p = 0.032) scores improved after rehabilitation compared with standard care. Compared with standard care, rehabilitation improved SARA scores at 30 weeks (mean difference −1.51, 95% CI: −2.76 to −0.27, p = 0.017), but not mFIM scores (1.74, 95% CI: −0.32 to 3.81, p = 0.098). Frequent adverse events in both groups were fatigue, pain, and falls. Interpretation: Goal-directed rehabilitation improved function at 7 weeks, with improvement in ataxia and health-related quality of life maintained at 30 weeks in individuals with HCA, beyond that of standard care. ANN NEUROL 2024.
UR - http://www.scopus.com/inward/record.url?scp=85208756286&partnerID=8YFLogxK
U2 - 10.1002/ana.27130
DO - 10.1002/ana.27130
M3 - Article
C2 - 39520242
AN - SCOPUS:85208756286
SN - 0364-5134
VL - 97
SP - 409
EP - 424
JO - Annals of Neurology
JF - Annals of Neurology
IS - 3
ER -